Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Carter v. Affymax, Inc. et al
Case Number:
3:13-cv-01025
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
July 03, 2014
Affymax To Pay $6.5M To End Class Action Over Anemia Drug
Biopharmacuetical company Affymax Inc. has agreed to pay $6.5 million to settle a class action alleging it knowingly misled investors about the dangers of its drug Omontys, which was recalled in 2013 after being linked to potentially deadly allergic reactions, according to documents filed Thursday in California federal court.
-
January 22, 2014
Affymax Largely Ducks Investor Suit Over Anemia Drug
A California federal judge on Tuesday trimmed a putative shareholder class action claiming Affymax Inc. and four executives misled investors about safety issues with anemia drug Omontys, ruling the plaintiffs hadn't shown most of the statements were intentionally misleading.
-
January 15, 2014
Affymax Says It Didn't Mislead Investors About Anemia Drug
Affymax Inc. urged a California federal judge to toss a proposed shareholder class action over its agreement to supply Fresenius Medical Care with anemia drug Omontys before the medication was recalled, arguing Wednesday that the plaintiffs haven't shown Affymax's statements to investors about the drug's safety were knowingly misleading.